(Q28283239)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20498641%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20498641%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20498641%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

S Wang

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20498641%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

X Huang

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20498641%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

C-K Lee

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20498641%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

language of work or name

English

0 references

publication date

24 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20498641%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20498641%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20498641%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

4225-4236

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20498641%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20498641%20AND%20SRC:MED&resulttype=core&format=json

Survivin knockdown combined with apoptin overexpression inhibits cell growth significantly

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Phosphotyrosine interactome of the ErbB-receptor kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Survivin, cancer networks and pathway-directed drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

The neu oncogene encodes an epidermal growth factor receptor-related protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Prognostic value of ERBB family mRNA expression in breast carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

The deaf and the dumb: the biology of ErbB-2 and ErbB-3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Trastuzumab--mechanism of action and use in clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Novel anti-tubulin cytotoxic agents for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Trastuzumab: triumphs and tribulations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Mechanisms of Taxol resistance related to microtubules.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Paclitaxel and docetaxel in the treatment of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Regulation of survivin expression by IGF-1/mTOR signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.180

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.180

2 references

Consolidated OpenCitations Corpus – April 2017

4044002

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20498641%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

3 February 2020

1028021238

0 references

4044002

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

4044002